Search clinical trials for: Basal Insulin Reduction

Total 14034 results

Institut de Recherches Cliniques de Montreal
McGill University Health Centre/Research Institute of the McGill University...

Recruiting

Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise (RIDE-2)

Type 1 Diabetes Mellitus

Canada
Ohio State University

Completed

Basal Insulin Strategies Before Surgery

Type2 Diabetes Mellitus
Sanofi

Completed

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (SPIRIT)

Type 2 Diabetes Mellitus

Ukraine
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Buckinghamshire Healthcare NHS Trust
Animas Corporation

Terminated

Managing Insulin Pumps for Exercise (Study 2)

Type 1 Diabetes

United Kingdom
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR); University of Toronto

Completed

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)

Type 2 Diabetes

Canada
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

Healthy | Diabetes

South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Assaf-Harofeh Medical Center

Unknown

Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study

Diabetes

Israel
Guillermo Umpierrez, MD
Medical University of South Carolina; Sanofi; Texas A&M University

Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (Basal-Plus)

Hyperglycemia | Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes (ProMix)

Diabetes Mellitus, Type 2 | Diabetes

Germany
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Heidelberg University

Unknown

Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells

Type 2 Diabetes

Germany
Novo Nordisk A/S

Completed

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Diabetes Mellitus, Type 2 | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Diabetes Mellitus, Type 2 | Diabetes

Morocco, Tunisia, Algeria, South Africa, Egypt
H. Lee Moffitt Cancer Center and Research Institute

Completed

Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia

Hyperglycemia

United States
Julphar Gulf Pharmaceutical Industries
Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal

Diabetes Mellitus

Germany
LMC Diabetes & Endocrinology Ltd.

Completed

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (VARIATION 2 SA)

Diabetes Mellitus, Type 2

Canada
Mayo Clinic

Completed

Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes

Type 1 Diabetes

United States
Eli Lilly and Company

Withdrawn

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Novo Nordisk A/S

Completed

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Consorci Sanitari Integral

Completed

Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes

Type 2 Diabetes Treated With Insulin
Hygieia, Inc
TKL Research, Inc.

Completed

Efficacy and Safety of Frequently Modified Intensive Insulin

Diabetes

United States
Eli Lilly and Company

Completed

A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus (CLASSIC)

Type 2 Diabetes Mellitus

China
University of Campania "Luigi Vanvitelli"

Completed

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (BEYOND)

Type 2 Diabetes

Italy
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (QWINT-5)

Diabetes | Type 1 Diabetes

United States, Taiwan, Japan, Poland, Argentina, Slovakia, Puerto Rico
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Type 2 Diabetes

United States, Spain, Taiwan, Japan, Poland, Argentina, Hungary, Puerto Rico, Korea, Republic of, Slovakia
Amalgam Rx, Inc.

Completed

A Digital Health Tool for Insulin Titration (DHIT) Individuals With Type 2 Diabetes: A Prospective Outcomes Study With a Retrospective Control Group (DHIT)

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)

Diabetes | Type 2 Diabetes

United States, China, Germany, Mexico, Brazil, Canada, Japan, Korea, Republic of, Puerto Rico, Czechia, Greece
Clinical Research Centre, Malaysia
Medtronic

Unknown

Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy

Type 2 Diabetes Mellitus

Malaysia
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Hyperglycemia

United States
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)

Type 2 Diabetes | T2D

United States, Mexico, Argentina, Puerto Rico
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States, Germany, Mexico, Argentina, Puerto Rico, Italy, Spain, India
Karolinska Institutet

Completed

Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes (SDIS)

Stroke | Renal Failure | Coronary Heart Disease

Sweden
Eli Lilly and Company

Completed

A Study of LY3192767 in Healthy Participants

Healthy

Germany
University of Virginia

Terminated

Glucagon Counterregulation in Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)

Type 2 Diabetes

Canada
University of Colorado, Denver

Completed

Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia

Type 1 Diabetes

United States
York University

Completed

Insulin Management for Exercise in Patients With Type 1 Diabetes

Hypoglycemia | Physical Activity | Type 1 Diabetes

Canada
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Health Care for Type 1 Diabetes in Developing World

Type 1 Diabetes

Rwanda
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Second Affiliated Hospital, School of Medicine,...

Recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Time in Range | HbA1c | Type 1 Diabetes Mellitus With Diabetic Gastroparesis

China
Institut de Recherches Cliniques de Montreal
Novo Nordisk A/S; McMaster University

Completed

Levemir-Body Composition and Energy Metabolism

Type 2 Diabetes

Canada

3

Subscribe